EPA
United States
Environmental Protection
Agency

Mechanistic Indicators of Childhood Asthma (MICA) -Integrating Environmental, Clinical and Susceptibility Markers to Improve the Impact of Human Air Pollution Studies.

Jane E. Gallagher Ph.D.
Human Studies Division
ORD NHEERL EPA

September 24-25 2007

Public Health Applications of Human Biomonitoring

EPA
United States
Environmental Protection
Agency

Advances in biomarker development have improved our ability to detect early changes at the molecular and cellular level.

EPA
United States
Environmental Protection
Agency



Battery of endpoints capturing Net effect–over several mechanisms of action/ classes

- Comet assay
- **P53**
- FISH
- 1-OH pyrene
- Cholinesterase inhibition
- Cross-linking metals formaldehyde
- HPRT
- DNA adducts methods
- **Mutagen sensitivity**
- **Oxidative damage**
- **Mutagenicity**

Integrated measure of dose across classes of chemicals

EvolvingTechnologies

United States Environmental Protection Agency

Environment Health Scientists

Clinicians



EPA United States Environmental Protection Agency

Environmental Studies Benefit from Knowledge Gained from Clinical Disease Studies (and visa versa)

- What factors affect a persons risk for a number of health conditions.
  - **Early indicators/detection of disease**
- Identify Genetic variants that increase susceptibility
- Determine whether the effect of genetic variants that increase risk is different in the presence of environmental exposures

EPA United States Environmental Protection Agency

MICA



?

?

?

Exposure

Clinical Disease





Biological Fluids/cells

EPA
United States
Environmental Protection
Agency

Change in research paradigm

- Work across disciplines
- Give up data for the greater good
- communicate

MICA-
Change Research Paradigm



EPA United States Environmental Protection Agency

MICA

- A childhood asthma study and Parallel rodent study
- A NHEERL and NCCT Computational Toxicology study
- Combines and Integrates biomarkers of exposure effects and susceptibility in the context of clinical measurements and disease (asthma) outcome.



EPA United States Environmental Protection Agency

National Center for Computational Toxicology

Goals

Improve linkages in the source to outcome paradigm

- Provide predictive models for Hazard ID
- Improve Quantitative Risk assessment Dose, species, chemical class

7 New Starts ---MICA

EPA
United States
Environmental Protection
Agency

RNA--- Blood Gene expression
DNA ----11 genes 55 SNP



SOURCE

HEALTH OUTCOME



INTERNAL DOSE

INTEGRATED DOSE

EARLY RESPONSES

MICA

Questionnaire
Diet
Time activity

Fingernails

urine

blood

Odor test

Lung function

NO ex





Asthma

Vacuum dust and

Passive monitoring

BMI
Blood Pressure
O2 Saturation
Cell differentials
Blood Chemistry
Cytokines
Creatinine
cotinine
Medications

EPA United States Environmental Protection Agency

MICA

Objective

Increase our understanding of asthma by assessing the complex gene/environmental relationships through the combined use of innovative methods to manage and analyze multifactorial data

MICA RODENT Phase 1

Childhood asthma Phase 2











11 polymorphic genes
55 SNP

MICA Nested Within Detroit Children's Health Study



EPA United States Environmental Protection Agency

National Exposure and Research Laboratory

Detroit Exposure Aerosol Research Study "DEARS"



EPA United States Environmental Protection Agency

MICA

- 200 children (asthma and no asthma) 9-12 years of age
- 100 families participated in self monitoring (indoor outdoor) as part of MICA air
- Vacuum Dust and medication list brought to clinic
- Educational and “station walk through” presentation to provide context to the study
- Consent assent and Questionnaire
- Lung function, NO ex and odor testing
- Blood, urine, fingernails collected

> 90 percent of subjects provided samples at each station.

MICA Childhood Study Multiple Risk Factors



Asthma studies by race



EPA United States Environmental Protection Agency

Study Design



Particulate matter (PM) (concentrated to 200-600µg/m^3)

Rodents: Blood and Lung Tissue

Detroit-area Urban Air

Gene Expression Profiles

Inflammatory Markers

Ambient Levels of PM and air toxics

Asthmatic and nonasthmatic Children n=200

Susceptibility Factors: Genetic Variation-RNA, DNA

Ambient Levels → Internal Dose → Effective Dose → Early Biological Effect → Pre-Clinical Effects → Clinical Disease

Biomarkers of Integrated Dose: Metals (Lead, Mercury), Metabolites of Polycyclic Aromatic Hydrocarbons, Cotinine, and Creatinine

Biomarkers of Early Effect: Autoantibodies, Mutagenicity Gene Expression Inflammatory Markers

Clinically-relevant Outcomes: Allergies, Asthma, Respiratory Symptoms, Lung Function NOex VOC

EPA
United States
Environmental Protection
Agency

- **Rodent Study**
- Detroit AIR
- Concentrated Air Particles Exposures

EPA
United States
Environmental Protection
Agency

MSU Mobile Air Research Laboratory (*AirCARE 1*)

J Harkema

Air Particle Concentrator and Inhalation Exposure System for Laboratory Rodents

Animals are exposed to concentrated fine and ultrafine particles in specially designed shoebox cages

MICA (I)

Evaluate Utility of Rodent models for analyzing gene expression data in childhood asthma study





EPA
United States
Environmental Protection
Agency







MICA

Study Design



Particulate matter (PM) (concentrated to 200-600µg/m^3)

Rodents: Blood and Lung Tissue

Detroit-area Urban Air

Gene Expression Profiles

Inflammatory Markers

Ambient Levels of PM and air toxics

Asthmatic and nonasthmatic Children n=200

Susceptibility Factors: Genetic Variation-RNA, DNA

Ambient Levels → Internal Dose → Effective Dose → Early Biological Effect → Pre-Clinical Effects → Clinical Disease

Biomarkers of Integrated Dose:
Metals (Lead, Mercury), Metabolites of Polycyclic Aromatic Hydrocarbons, Cotinine, and Creatinine

Biomarkers of Early Effect:
Autoantibodies, Mutagenicity
Gene Expression
Inflammatory Markers

Clinically-relevant Outcomes:
Allergies, Asthma, Respiratory Symptoms, Lung Function
NOex VOC

Gene expression - RNA
Genotyping –DNA (11 genes 55 SNP)

Indoor outdoor

- PAH VOC No2
- O3
- Allergens
- Molds

Metals
- Heavy Metals
- PAH metabolites
- ETS
- Pb Hg
- Napthols
- Phenanthrols

ROS
- Cholinesterase
- Mutagenicity
- 1 OH Pyrene
- Antibodies to nervous system
- Cotinine
- proteins
- Coagulation factors

Lung function
- NOex
- Antioxidants
- Allergen skin testing
- Plasma ROS
- Cytokines
- Blood panel
- Cell surface markers

Passive monitoring: NO_2, PAHs VOC, (indoor and outdoors)

Vacuum dust	Metals, PAHs,aero-allergens mold, endotoxin)

Biomarkers--- Clinical and Environmental

Urine	Cotinine Creatinine
Urine	Metals: Mercury, Cadmiun, Arsenic, Chromium, Manganese, Nickel
Urine	1- hydroxpyrene (1-OH pyrene) Napthols, Phenanthrols, Hydrocarbon Metabolites phthalates
Urine	Mutagenicity Assays
Serum	Autoantibodies for nervous system proteins, Blood Chemistry, Total IgE and specific antibodies to common aero-allergens (multiscreen inhalant and food antibody series)- *dust mite, Cockroach , Mouse, Rat Urine Protein,
Plasma	Reactive Oxygen Species, cytokines (IL4, 6 IL13), tumor necrosis factor-alpha, c-reactive protein, fibrinogen
Whole Blood	hematology panel, lead and mercury, Gene expression (RNA), glycosolated hemoglobin
Nails	Mercury, Cadmium, Arsenic, Chromium, Manganese, Nickel
Serum	IgE-inducing proteins associated with fungal exposures

















11 polymorphic genes
55 SNP

NOW WHAT ???

EPA United States Environmental Protection Agency









































































CINCINNATI CHILDRENS HOSPITAL

J ALLERGY CLIN IMMUNOL
VOLUME 115, NUMBER 2

NORMAL

Stable Asthmatics

UnStable Asthmatics

NASAL EPITHELIAL CELLS



Jesus R. Guajardo, MD, MHPE,[a] Kathleen W. Schleifer, PhD,[b] Michael O. Daines, MD,[a] Richard M. Ruddy, MD,[c] Bruce J. Aronow, PhD,[d] Marsha Wills-Karp, PhD,[b] and Gurjit K. Khurana Hershey, MD, PhD[a] *Cincinnati, Ohio*

EPA
United States
Environmental Prote
Agency

Elaine Hubal
David Reif
National
Center for
Computational
Toxicology



Subjects

Biomarkers Exposure/Clinical indicators

EPA United States Environmental Protection Agency

Biomarker Needs

- Exposure biomarkers in the context of clinical health indicators
- Mechanistic information test biological plausibility in rodents
- Validation of surrogate cells with target tissue responses

Archiving of biological and environmental samples and measurements as new technologies advance

Summary

- High-data content technologies, elucidating the genetic and environmental basis for toxicity and disease



Integration of Diverse Set of exposure, effects and susceptibility





Gene expression arrays

bioinformatic



computational

statistical analysis.



genes, pathways, and networks

Acknowledgements












PHASE II MICA

National Health Exposure and Effects Laboratory

Stephen Edwards
Elaine Hubal
David Reif

National Center for Computational Toxicology

Acknowledgements

Westat

Henry Ford Health System

Clinic

Henry Ford Health System-lab

Acknowledgements

MICA-HSD
Ed Hudgens
Gina Andrews
Brooke Heidenfelder
Jeff Inmon
Mary Johnson
Danelle Lobdell
Pauline Mendola
Jim Prah
Scott Rhoney
Elizabeth Sams
DCHS
Lucas Neas
Ann Williams
NCCT
Elaine Hubal
David Reif
Administrative
Walter Breyer
Edward Strubble
Mike Ray QA
Debra Walsh
Kay Williams

Nurses HSD
Mary Ann .Bassett
Deb Levin
Tracy. Montilla
Westat
Andrea Ware
IRB
Richard Herman
Monica Nees
Contracts
Robin Harris
Jennifer Hill
Lenora Hilliard
Student Contractors
Chris Garlington
Chrissy Lin
Sharon Myers
Peter Stone

NERL
Shaibal Mukergee
Haluk Ozkaynak
Ron Williams
Dan Vallero
NERL Cincinnati
Stephen Vesper

ETD
Gary Hatch
Marsha Ward et al
Kay Crissman
McGee

Genomics core
Susan Hester
Chris Corton
NHEERL Office of the Director
Stephen Edwards
ECD
David DeMarini
Region 5
George Bollweg
Jackie Nwai

Michigan State U.
J. Harkema
Lori Bramble

Mercy College
H. El Fawal
Johns Hopkins
Robert Hamilton
John Wiseman
Carol Schultz
Harvard University
Rutgers University
Tina Fain
UNC
Stephen Rappaport
Suryamya W.
SWRI
David Caaman
RTI
Frank Weber
Peter Groshe
Westat
Kurt Patrizi
Henry Ford Health System
Clinical and Lab